The human c-rel proto-oncogene (REL) encodes a subunit of the nuclear factor-kappaB (NF-jB) transcription factor. In this report, we have identified an identical point mutation in two human B-cell lymphomas (follicular (FL) and mediastinal) that changes serine (Ser)525 (TCA) to proline (Pro) (CCA) within the REL transactivation domain. This mutation was not identified in a similarly sized cohort of healthy individuals. In the mediastinal B-cell lymphoma, the mutation in REL is of germ-line origin. In both tumors, the S525P mutant allele is overrepresented. REL-S525P shows enhanced in vitro transforming activity in chicken spleen cells. REL-S525P has a reduced ability to activate the human manganese superoxide dismutase (MnSOD) promoter in A293 cells; however, the MnSOD protein shows increased expression in REL-S525P-transformed chicken spleen cells as compared to wild-type REL-transformed cells. Ser525 is a site for phosphorylation by IjB kinase (IKK) in vitro. The S525P mutation reduces IKKa-and tumor necrosis factor (TNF)a-stimulated transactivation by a GAL4-REL protein. Furthermore, REL-S525P-transformed chicken spleen cells are more resistant to TNFa-induced cell death than cells transformed by wild-type REL. These results suggest that the S525P mutation contributes to the development of human B-cell lymphomas by affecting an IKKa-regulated transactivation activity of REL.
Introduction
The human c-rel proto-oncogene (REL) encodes a nuclear factor-kappaB (NF-kB) family transcription factor. Expression of c-rel is important for normal and malignant B-cell proliferation. c-rel knockout mice have normal numbers of mature B cells, but these cells do not proliferate in response to mitogenic stimulation (Ko¨nt-gen et al., 1995) . Conversely, overexpression of chicken, mouse or human c-rel can transform chicken lymphoid cells in vitro and these cells can form lethal lymphomas in chickens (Gilmore et al., 2004) . In addition, the REL locus is amplified in several types of human B-cell lymphoma, including diffuse large B-cell lymphomas (DLBCLs), follicular lymphomas (FLs) and primary mediastinal lymphomas (Gilmore et al., 2004) . Moreover, REL mRNA is highly expressed in de novo DLBCLs, and this elevated expression correlates with increased expression of many REL target genes (Rhodes et al., 2005) .
REL is a 587 amino acid (aa) polypeptide that binds DNA as a dimer, either as a homodimer or in a dimer with other NF-kB family members (Gilmore et al., 2004) . REL contains an N-terminal Rel homology domain, which mediates DNA-binding, dimerization, nuclear localization and binding to its inhibitor, IkB. The C-terminal half of REL (aa 296-587) contains a transactivation domain, which is comprised of at least two subdomains: subdomain I (aa 422-497) and subdomain II (aa 518-587) (Martin et al., 2001; Starczynowski et al., 2003) . The REL C-terminal transactivation domain can also be regulated by phosphorylation of specific serine (Ser) residues (Fognani et al., 2000; Martin and Fresno, 2000; Martin et al., 2001; Yu et al., 2004; Lawrence et al., 2005; Harris et al., 2006) . Recently, IkB kinase (IKK)-associated kinases have been found to phosphorylate C-terminal residues of REL in an immune complex kinase assay (Lawrence et al., 2005; Harris et al., 2006) .
Altered transactivation by REL is also correlated with increased oncogenicity. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of REL in chicken spleen cells, but such deletions reduce the overall transactivation ability of REL (Starczynowski et al., 2003) . Mutation of certain tumor necrosis factor (TNF)a-responsive Ser residues in the transactivation domain also enhances REL's in vitro transforming ability and alters its ability to transactivate certain kB site-containing promoters (Starczynowski et al., 2005) .
In this report, we describe a point mutation in two human B-cell lymphomas that changes a conserved Ser residue at aa 525 to proline (Pro) within the transactivation domain. The REL-S525P protein has an enhanced ability to transform chicken spleen cells, and shows alterations in transactivation of certain reporter genes and in phosphorylation by IKK. This is the first evidence suggesting that point mutations in REL contribute to human B-cell lymphomagenesis.
Results

Mutation screening of B-cell lymphomas identifies two mutant REL alleles
The entire C-terminal transactivation domain of REL is encoded by a single exon (exon 10) (see Figure 2a , below). In a screening of exon 10 sequences from 83 Bcell lymphomas, we identified an identical point mutation (TCA-CCA) that changes codon Ser525 to Pro within the REL transactivation domain in two human B-cell lymphomas (Figure 1b) . Case 1 was diagnosed as FL and Case 2 as mediastinal B-cell lymphoma (Table 1) . Cytogenetic and molecular cytogenetic analyses showed the characteristic chromosomal changes in both cases, that is, t(14;18)(q32;q21) involving IGH and BCL2 in Case 1 and tetrasomy 9 in Case 2. The full karyotypes are presented in Table 1 . Interphase fluorescence in situ hybridization (FISH) analyses with probes for chromosome 2 showed coamplification of the BCL11A/REL loci in Case 2, but a normal diploid pattern in Case 1. In Case 2, the S525P mutation was also present in a peripheral blood sample lacking molecular evidence of lymphoma infiltration, suggesting a germ-line origin for the mutation. Unaffected tissue was not available for Case 1. Quantitative allelic discrimination of the two S525P mutations indicated that the mutant REL allele is over-represented in both tumor tissues, but not in normal peripheral blood cells from Case 2 (Table 1) . Denaturing high performance liquid chromatography (DHPLC) screening of genomic DNA from 166 healthy adults did not identify any individual with this REL mutation, indicating that S525P REL allele is not a common polymorphism, and a chi-squared analysis indicates that the frequency of the S525P allele in the tumor samples is statistically different from the healthy samples (Po0.05). Ser525 is conserved from chicken to human c-Rel (Figure 1b) , even though the C-terminal transactivation domain residues from various vertebrate c-Rel proteins share little overall aa identity (Figure 1b) .
REL-S525P has enhanced transforming ability in chicken spleen cells
We next determined whether the S525P mutation affects REL's transforming ability. The ability of REL-S525P Figure 1 A mutation from Ser to Pro at aa 525 of REL was identified in two cases of human B-cell lymphoma. (a) DHPLC mutational screening of 83 non-Hodgkin's lymphomas and subsequent cloning and sequencing revealed the mutation TCA to CCA (S525P) in REL exon 10 in two cases. The mutation leads to an altered DHPLC pattern (red) as compared to the wild-type sequence (blue, green and yellow). (b) Alignment of human c-Rel residues 509-536 to the corresponding c-Rel residues from different species. The conserved Ser(Ser525 in human REL) is indicated in bold. In peripheral blood of patient 2, the MUT:WT allele ratio was 50:50.
Activating mutation in REL DT Starczynowski et al to transform chicken spleen cells was compared to wildtype REL and to RELD424-490 (which lacks transactivation subdomain I and has increased transforming activity (Starczynowski et al., 2003) ). In a liquid outgrowth assay for transformation (Gilmore et al., 2001) , REL-S525P transformed cells significantly (Po0.05) faster than wild-type REL (Figure 2b ): over several assays, REL-S525P transformed these cultures in an average of 17.5 days, whereas wild-type REL transformed the cultures in 19.5 days. As expected, RELD424-490 also transformed significantly faster (15.3 days) than wild-type REL (Figure 2b ). The expression and activity of REL-S525P and wildtype REL were compared in transformed spleen cells in three ways. First, Western blotting showed that cells transformed by REL-S525P and REL expressed comigrating proteins (see Figure 5b , below); moreover, the steady-state levels of REL and REL-S525P were similar in transformed cells. Second, the primarily cytoplasmic immunofluorescence staining patterns and nuclear abundance (by biochemical fractionation) of REL and REL-S525P in transformed chicken spleen cells were indistinguishable (Figure 3a and b) . Third, nuclear extracts from REL-and REL-S525P-transformed cells contain approximately equal kB-site DNA-binding activity (Figure 3c ). These results demonstrate that REL-S525P transforms chicken spleen cells more efficiently than wild-type REL, even though the expression, subcellular localization and DNA-binding activity of REL are not affected by the S525P mutation.
REL-S525P differs from wild-type REL in its ability to transactivate kB site-containing promoters We next compared transactivation by full-length REL and REL-S525P on three kB site-containing reporter plasmids in transient transfection assays in human A293 cells. REL-S525P showed slight, but statistically significant, differences from wild-type REL in its ability to activate transcription from two of the three promoters. Although wild-type REL and REL-S525P transactivated the IkBa promoter equally well, REL-S525P activated a multimeric (3X) kB-site promoter approximately twofold greater than wild-type REL (Figure 4a and b). In contrast, REL-S525P was less effective than REL at transactivating the human manganese superoxide dismutase (MnSOD) (SOD2) promoter (Figure 4c ). Reduced transactivation of the SOD2 Activating mutation in REL DT Starczynowski et al promoter is a property that REL-S525P shares with the more highly transforming REL mutant, RELD424-490 (lacking transactivation domain I; Figure 4c ). Western blotting of extracts from the reporter gene assays shows that REL and REL-S525P were expressed at approximately equal levels ( Figure 4d ).
To determine whether the difference between the ability of REL and REL-S525P to induce the SOD2 promoter reporter gene is reflected in the expression of the endogenous SOD2 gene, we compared human manganese superoxide dismutase (MnSOD) protein levels in both transiently transfected A293 cells and chicken spleen cells stably transformed by REL or REL-S525P. As a control, we also measured MnSOD protein levels in cells expressing REL-S533,536A, a mutant that behaves similarly to wild-type REL in transformation and transactivation assays (Martin et al., 2001; Starczynowski et al., 2005) . The level of MnSOD protein in A293 cells overexpressing REL-S525P was approximately 4.5-fold higher than in cells transfected with the vector control, whereas the levels of MnSOD protein in cells overexpressing wild-type REL or REL-S533,536A were approximately 7.5-fold higher than in control cells ( Figure 5a ). In contrast, the increase in endogenous IkBa expression was similar in A293 cells overexpressing either REL or REL-S525P (Figure 5a ), which is consistent with reporter assays in which REL and REL-S525P activated the IkBa promoter equally well ( Figure 4a ). In contrast to the results in A293 cells, MnSOD protein levels were approximately twofold higher in spleen cells transformed by REL-S525P than in cells transformed by wild-type REL (Figure 5b ).
Therefore, REL-S525P appears to alter the expression of endogenous MnSOD protein differently than wildtype REL in these two different cell types. Taken together, these results indicate that the S525P mutation alters the transactivation properties of REL on some kB site-containing promoters.
Ser525 is a site for IKK-mediated phosphorylation in vitro and mutation of Ser525 reduces the ability of IKKa to increase GAL4-REL-mediated transactivation We noted that Ser525 lies within an aa sequence that resembles IKK-targeted Ser residues in IkBa (Ser32, Ser36) and in RelA/p65 (Ser536) (Figure 6a ). To determine whether Ser525 in REL is a substrate for IKK-mediated phosphorylation, FLAG epitope-tagged IKKa or IKKb were purified from transfected A293 cells and their abilities to phosphorylate GST-REL (aa 500-530) or GST-REL-S525A (aa 500-530, in which Ser525 is replaced by alanine (Ala)) were measured in immune complex kinase assays (Figure 6b ). IKKa and IKKb each phosphorylated GST-REL, but not GST-REL-S525A, indicating that Ser525 is a site for IKK phosphorylation. Coomassie blue (CB) staining of the same gel used to detect phosphorylated GST-REL shows equal loading of both GST-REL proteins and the FLAG--IKK proteins (Figure 6b ).
To determine whether IKKa and IKKb can affect REL's transactivating ability, we performed reporter gene assays using GAL4-REL fusion proteins containing the transactivation domain (aa 278-587) from wildtype REL or REL-S525P. A293 cells were transfected with expression plasmids for GAL4-REL or GAL4-REL-S525P plus either vector alone, IKKa, or IKKb, and a luciferase reporter gene containing GAL4 DNAbinding sites. IKKa and IKKb increased transactivation by GAL4-REL above vector alone levels by approximately three-and fourfold, respectively (Figure 6c ). IKKa was less effective at inducing transactivation by GAL4-REL-S525P than by GAL4-REL, and IKKbinduced GAL4-REL-S525P transactivation was slightly reduced as compared to GAL4-REL (Figure 6c ). FLAG-IKKa and FLAG-IKKb were expressed at equal levels in cells transfected with either the GAL4-REL or GAL-REL-S525P expression plasmids ( Figure 6d) ; however, FLAG-IKKa is expressed at lower levels than FLAG-IKKb, and therefore, the effect of IKKa on GAL-REL transactivation may be larger than seen here. As a control, we also show that GSK3b did not induce higher levels of REL-mediated transactivation (Figure 6c ), indicating that IKKa and IKKb specifically increase transactivation by REL. These results indicate that IKKa and IKKb can both enhance REL's transactivating ability, and they suggest that Ser525 is required for full IKKa-induced transactivation by REL.
To assess the ability of IKKa and IKKb to phosphorylate the C-terminal transactivation region of REL, we compared the ability of FLAG-IKKa and FLAG-IKKb to phosphorylate GST-REL and GST-REL-S525P proteins containing aa 323-587 (Figure 6e ). GST-REL-S525P showed a reduced level of phosphorylation by IKKa as compared to GST-REL (lanes 3 and 4), whereas phosphorylation of GST-REL and GST-REL-S525P by IKKb were more similar (lanes 5 and 6). Neither GST-REL protein was phosphorylated in immune complex kinase assays performed with immunoprecipitates from cells transfected with an expression vector for FLAG alone. These results suggest that there are multiple IKK phosphorylation sites, in addition to Ser525, in the C-terminal half of REL.
Mutation of Ser525 to proline impairs TNFa-induced signaling to REL Ser525 has not been previously identified as a TNFaresponsive Ser residue in REL (Martin and Fresno, 2000; Martin et al., 2001; Starczynowski et al., 2005) . To determine whether TNFa can enhance transactivation by REL-S525P, we performed GAL4-REL reporter gene assays in A293 cells in the presence and absence of TNFa. Consistent with our previous results (Starczynowski et al., 2005), TNFa treatment increased transactivation by GAL4-REL (Figure 7a ). In contrast, transactivation by GAL4-REL-S525P was not significantly changed by treatment with TNFa. A possible phosphomimetic mutant at Ser525 (S525D) did not significantly affect the inherent or TNF-induced transactivating ability of GAL4-REL or the ability of fulllength REL to transform chicken spleen cells (Table 2) .
To determine whether the S525P mutation affects the ability of TNFa to induce cell death, we compared the effect of TNFa on the viability of spleen cells transformed by REL or REL-S525P. Spleen cells transformed by wild-type REL were incubated with increasing concentrations of TNFa for 16 h and the viability of the cells was then determined by Trypan blue dye exclusion; the concentration of TNFa that induced maximal cell death of REL-transformed spleen cells is 250 nM (data not shown). Therefore, we treated RELand REL-S525P-transformed spleen cells with 250 nM TNFa for 16 h and measured cell viability by Trypan blue dye exclusion. After a 16-h treatment with TNFa, approximately 60% of REL-transformed cells were dead (Figure 7b ). In contrast, REL-S525P-transformed cells showed no increased cell death after TNFa treatment. Wild-type REL-and REL-S525P-transformed cells contained 25-40% dead cells under normal conditions without TNFa treatment. As such, RELtransformed cells had a 1.4-fold increase in cell death after TNFa treatment. This result suggests that spleen cells transformed by REL-S525P are less sensitive to TNFa-induced cell death as compared to cells transformed by wild-type REL. In contrast, REL-and REL-S525P-transformed cells each showed similar levels of cell death (approximately 60% dead cells) after treatment with CHX (10 mg/ml) for 16 h (Figure 7b ), Figure 6c , GAL4-fusion proteins containing C-terminal transactivation domains from the indicated proteins were co-transfected with a GAL4-site luciferase reporter. Twenty-four hours after transfection, cells were starved for 16 h and were then stimulated with TNFa ( þ ) or left untreated (À) (values were normalized to untreated cells in each case). (b) Chicken spleen cells transformed by wild-type REL or REL-S525P were treated with TNFa (250 nM) or CHX (10 mg/ml) for 16 h, and cell viability was determined by Trypan blue exclusion. Transactivation from a GAL4-site luciferase reporter gene was assayed in A293 cells that had been treated with TNF, as in Figure 7a . Each value is the ratio of the luciferase activity obtained with the given GAL4-REL protein in the presence vs the absence of TNF.
c Transformation of chicken spleen cells was determined in two assays that had a total of 12 plates for wild-type REL and 16 plates for REL-S525D. The relative times for the REL-S525D plates to become transformed were then normalized to the average time it took for wildtype REL to transform the plates in each assay (100), as in Figure 2b. demonstrating that REL-S525P cells are not generally more resistant to cell toxins.
Discussion
In this report, we describe a REL mutant (S525P) identified in two B-cell human lymphomas that has an enhanced in vitro transforming ability, providing the first evidence of a point mutation in REL that may contribute to the development of human lymphoma. The S525P-REL mutation (CCA at codon 525) has an allele frequency of approximately 1.2% (2/166) in the 83 B-cell lymphomas that we screened, and appeared to be of a germline origin in the individual for whom nonlymphoma tissue was available. The screening of 166 healthy individuals did not detect the S525P mutation, suggesting that the frequency of the S525P allele is less than 0.3% (0/332) in the non-disease population. Analysis of the Single Nucleotide Polymorphism database (build 125, September 2005) on the UCSC Genome Browser (http://genome.ucsc.edu/) did not show a common polymorphism in exon 10 of REL. These results suggest that the S525P allele is quite rare. If the S525P mutation does contribute to lymphoma development, the mutation may be a pre-disposing, rather than a tumor-specific, somatic mutation. We cannot predict the lymphoma risk in individuals with the S525P mutation because neither the frequency of this mutation in the normal population nor the percentage of S525P-carrying individuals who develop lymphomas is known.
Our data show that REL-S525P has effects on promoters that are distinct from wild-type REL. Namely, the S525P mutation affects REL's transactivating ability on the SOD2 and 3X-kB site promoters in different ways: REL-S525P induces decreased transactivation of the SOD2 promoter, but increased transactivation of the 3X-kB site promoter. Similar promoter context variability has also been seen when the IKK site Ser536 in RelA is mutated; that is, RelA-S536A transactivates the intercellular cell adhesion molecule (ICAM)-1 promoter more efficiently than wild-type RelA, but activates the IL-8 promoter weaker than RelA (Sasaki et al., 2005) .
Although REL-S525P activates the SOD2 promoter less effectively than wild-type REL in transient transfection assays in A293 cells, there are increased levels of SOD2 protein in chicken spleen cells transformed by REL-S525P as compared to cells transformed by wildtype REL. We have recently shown that mutations at Ser460 or Ser471, which enhance REL's transforming ability, also affect MnSOD expression in opposite ways in A293 cells versus chicken spleen cells (Starczynowski et al., 2005) . As discussed therein, the differences in MnSOD expression in transient transfection experiments in A293 cells versus in stably transformed chicken spleen cells may reflect the kinetics of REL-induced gene expression. That is, the ability of REL-S525P initially to induce lower level expression of some genes, such as SOD2, may result in higher long-term expression of these genes and their products, similar to results seen with chicken c-Rel versus v-Rel on the IAP1 promoter (Kralova et al., 2002) . A role for increased MnSOD expression in lymphomas is suggested by cDNA microarray analyses that show that SOD2 mRNA expression is elevated in human mediastinal lymphomas and in chicken bursal lymphoma cells (Neiman et al., 2003; Feuerhake et al., 2005) .
Several reports suggest that the C-terminal transactivation domain of REL is a substrate for signal-induced phosphorylation, which affects REL's transactivation properties. In particular, stimulation with TNFa can increase transactivation by GAL4-REL proteins containing the isolated REL transactivation domain (Martin and Fresno, 2000; Martin et al., 2001; Starczynowski et al., 2005) . Similar to S525P, mutation of certain TNFa-inducible Ser residues (Ser460 and Ser471) enhances REL's transforming ability and alters its ability to transactivate some kB site-containing promoters (Starczynowski et al., 2005) . As such, these TNFaresponsive Ser residues in REL (Ser460, 471 and 525) could be sites of phosphorylation catalysed by a kinase(s) downstream of the TNFa receptor, and phosphorylation of these Ser residues would be expected to increase transcription of TNFa-targeted REL-dependent genes. Nevertheless, none of these Ser has been demonstrated to be phosphorylated in vivo, moreover, a phosphomimetic Asp mutation at Ser525 does not affect basal or TNF-induced transactivation by GAL4-REL (Table 2) , raising the possibility that Ser525 contributes to REL transactivation in a way other than through regulated phosphorylation.
The catalytic subunits of the IKK complex, IKKa and IKKb, have substrates besides IkB (Scheidereit, 2006) . IKK-and NIK-associated kinases have been shown to phosphorylate sites within residues 422-540 of REL in vitro (Lawrence et al., 2005; Harris et al., 2006; Sa´nchez-Valdepen˜as et al., 2006) , and we show that both IKKa and IKKb can phosphorylate Ser525 of REL in vitro. However, Ser525 appears to be only one of multiple sites in the C-terminal, half of REL that can serve as in vitro phosphorylation sites for IKK, given that a fragment containing the entire C-terminal REL transactivation domain with the S525P mutation has only a slightly reduced ability to be phosphorylated by IKKa and IKKb in vitro (Figure 6b and e) . The results of Lawrence et al. (2005) suggest that phosphorylation of REL C-terminal sequences (which include Ser525) by an IKKa-dependent kinase increases the turnover of REL complexes in the nucleus and promotes the removal of REL from target gene promoters. We have not, however, detected a difference in the stability of REL and REL-S525P proteins in transformed chicken spleen cells (data not shown). More recently, Harris et al. (2006) have shown the phosphorylation of C-terminal residues in REL by IKKb promotes its dissociation from IkBa and its nuclear accumulation.
REL-S525P-transformed cells are less sensitive than wild-type REL-transformed cells to the killing effects of TNFa. The simplest hypothesis to explain these results is that TNFa stimulates REL to activate the expression of a set of genes that are incompatible with transformed spleen cell viability. REL-S525P may not respond to this TNFa-induced cell-death stimulus. TNFa is known to act as a regulator of steady-state hematopoiesis (Bryder et al., 2001) ; thus, circulating TNFa may contribute to the maintenance of B-cell homeostasis by promoting cell death. In some cases, TNFa-antagonist therapy for inflammatory diseases has been associated with an increased risk of developing non-Hodgkin's B-cell lymphoma (Brown et al., 2002) . Taken together, such findings suggest that decreased levels of TNFa would cause B-lymphocytes to be eliminated less efficiently, which would increase the potential for lymphoma development. Similarly, a mutation (such as S525P) that reduces the responsiveness of REL to a TNFadependent death signal would be expected to promote B-cell survival.
Materials and methods
Tumor and normal blood samples Tumor samples were obtained from 19 FL and 64 aggressive B-cell lymphomas within the 'Deutsche Krebshilfe' funded network 'Molecular Mechanisms in Malignant Lymphoma', for which ethics approval from the Institutional Review Board was obtained. All tumor samples underwent histological review by members of the reference pathologist panel of the Deutsche Krebshilfe network. Diagnoses of B-cell lymphoma were established according to World Health Organization (WHO) criteria (Harris et al., 1999) . In the two patients with REL mutations, the diagnoses of FL and mediastinal lymphoma were confirmed. In the patient with the mediastinal B-cell lymphoma, a peripheral blood sample was available in which tumor infiltration was less than 0.1% as judged by clonality analysis using IGH-PCR (FR-1-3) (van Dongen et al., 2003) . For normal controls, DNA from peripheral blood was obtained from 166 healthy donors.
Karyotyping and fluorescence in situ hybridization Chromosome analyses from tumor samples were performed on unstimulated short-term cultures. Harvesting, slide preparation and R-banding were performed as described (Schlegelberger et al., 1999) . Results were documented using the IKAROS system (Metasystems, Altlussheim, Germany). Description of the karyotypes followed the rules of the International System for Human Cytogenetic Nomenclature (Mittlemann, 1995) . FISH with the LSI IGH-BCL2 doublecolor double-fusion probe (Vysis, Downers Grove, IL, USA) and for the REL locus were performed on cells left from the cytogenetic analysis and cryosections of tumor tissue as described (Joos et al., 2003; Martı´n-Subero et al., 2002 .
Polymerase chain reaction amplification Genomic DNA was extracted from lymph node samples and peripheral blood by standard methods. The 770 bp region containing REL exon 10 sequences was amplified using the Expand High-Fidelity polymerase chain reaction (PCR) System (Roche, Mannheim, Germany) to generate three partially overlapping PCR products. See Supplementary information for details of PCR amplification.
Denaturing high performance liquid chromatography Screening for REL mutations was performed by highthroughput DHPLC using the Transgenomic WAVE DHPLC system (Transgenomic Inc., Omaha, NE, USA). The gradient was compounded by buffer A (0.1 mM TEAA) and buffer B (0.1 M TEAA, 25% acetonitrile). Measurements were carried out at a flow rate of 0.9 ml/min, with a gradient increase of 2.5%/min buffer B for 4.2 min. DHPLC electropherograms were evaluated with Navigator software. Serial dilutions of mutated in unmutated PCR products showed a sensitivity limit for mutation discovery of less than 5%.
Cloning and sequencing of REL mutants PCRs of REL genomic DNA were carried out from both strands and subjected to direct sequencing with the BigDye Termination sequencing chemistry (Applied Biosystems (ABI), Foster City, CA, USA).
In the two samples with exon 10 REL mutations, purified PCR amplicons were subcloned into pGEM-T (Promega, Madison, WI, USA). All amplicons were subjected to DNA sequencing.
Quantitative allelic discrimination
The ABI SNaPshot Multiplex System was used for quantitative allelic discrimination of REL S525P in tumor samples and in peripheral blood. A standard curve was generated using mixtures of unmutated 525CC and mutated 525TT DNA in serial dilutions with increasing ratios (0%, 5%, 20% up to 100% mutated 525TT DNA). Analyses were performed in triplicate and analysed on an ABI 3100Avant Genetic Analyzer. PCR and thermocycling were according to the manufacturer's instructions. The logged TAMRA (ddCTP) and ROX (ddTTP) signals were analysed using ABI GeneScan Software and were estimated from the generated standard curve.
Plasmids
Complete details of all primers and subclones used to create plasmids can be obtained in the Supplementary information.
Cells and spleen cell transformation assays A293 human embryonic kidney cells and transformed chicken spleen cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10-20% fetal bovine serum (FBS) (Biologos, Montgomery, IL, USA) as described (Starczynowski et al., 2005) . Spleen cell transformation was measured in a liquid outgrowth assay (Gilmore et al., 2001; Starczynowski et al., 2003 Starczynowski et al., , 2005 , and cultures were scored as transformed on the day when transformed cells began to overgrow the culture as judged by acidification of the medium.
Western blotting, indirect immunofluorescence and electrophoretic mobility shift assays Western blotting and indirect immunofluorescence were performed as described previously (Starczynowski et al., 2003 (Starczynowski et al., , 2005 . Details of antisera are in the Supplementary information.
Electrophoretic mobility shift assays (EMSAs) for kB site binding were performed using 5 mg of nuclear extracts as described previously (Kalaitzidis et al., 2002; Starczynowski et al., 2005) . For supershift assays, 1 ml of REL antiserum was added after protein/DNA complex formation and reactions were incubated on ice for an additional hour (Kalaitzidis et al., 2002) .
Luciferase reporter gene assays For GAL4 reporter assays, A293 cells in 35-mm plates were transfected with 0.5 mg of reporter plasmid GAL4-site luc, 0.5 mg of normalization plasmid pCMV-b-galactosidase (bgal) and 1 mg of the given pSG424-based GAL4 expression plasmid using the Superfect Reagent (Qiagen, Valencia, CA, USA). For kB-site luciferase reporter gene assays, A293 cells were transfected with 0.5 mg of luciferase reporter plasmid, 0.5 mg of pGK-bgal and 1 mg of the given pcDNA expression plasmid. The 3 Â kB-site pGL2 reporter plasmid the chicken IkBa promoter reporter plasmid, and the human SOD2 promoter reporter plasmid have been described previously (Starczynowski et al., 2005) .
For co-expression studies with IKK and GAL4-REL proteins, 0.8 mg of pSG-REL and 0.8 mg of pcDNA-FLAG plasmids were used. For TNFa induction assays, A293 cells were transfected with 0.5 mg of reporter plasmid GAL4-site luc, 0.5 mg of normalization plasmid pGK-bgal and 1 mg of pSG424-based GAL4 expression plasmids. The following day, cells were grown in 1% FBS for 16 h, and then either treated or not with 20 ng/ml of TNFa (R&D Systems, Minneapolis, MN, USA).
Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, WI, USA). Luciferase values were normalized to bgal values in all assays (Kalaitzidis et al., 2002; Starczynowski et al., 2005) .
Kinase assays IKK kinase assays were performed as described previously (Liang et al., 2003) . After heating at 901C in sodium dodecyl sulfate (SDS) sample buffer, samples were electrophoresed on 7.5% SDS-polyacrylamide (SDS-PAGE) gels. Gels were washed with water for 30 min, stained with CB for 30 min, destained for 1 h, dried and subjected to phosphorimaging to detect 32 P-labeled GST-REL proteins.
Cell killing assays
The sensitivity of cells to TNFa or CHX was determined by Trypan blue exclusion. REL-transformed cells in measured aliquots were plated in 24-well plates and treated with the indicated amount of human recombinant TNFa (R&D Systems, Minneapolis, MN, USA) or CHX (Sigma, St Louis, MO, USA) for 16 h. Blue cells were counted using a hemocytometer. Individual counts of approximately 100 cells were performed at least three times for a given treatment with triplicate counts in each experiment.
